Why do you believe the results of LEADER, showing CV outcome reduction with liraglutide, are different from previous trials using GLP-1 RAs that failed to demonstrate CV risk reduction?

Why do you believe the results of LEADER, showing CV outcome reduction with liraglutide, are different from previous trials using GLP-1 RAs that failed to demonstrate CV risk reduction?

Why do you believe the positive results of the LEADER trial, showing CV outcome reduction with liraglutide, are different from previous trials using other GLP-1 RAs that failed to demonstrate CV risk reduction?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Luc Van Gaal, MD

Luc Van Gaal, MD

Professor of Medicine
Department of Endocrinology, Diabetology and Metabolism
Antwerp University Hospital
Antwerp, Belgium